AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22411933
Drug: eGFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <60 ml/min/1.73 m(2) at entry
Trial: 22411933
Drug: eGFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <60 ml/min/1.73 m(2) at last day of follow-up
Trial: 22415795
Drug: Saracatinib 50
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 50 mg
Trial: 22415795
Drug: Saracatinib 125
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 125 mg
Trial: 22415795
Drug: Saracatinib 175
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 175 mg
Trial: 22415795
Drug: Saracatinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib (all doses)
Trial: 22415951
Drug: Intraspinal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraspinal infusion of autologous bone marrow mononuclear cells (BMNCs)
Trial: 22416063
Drug: CBT-1® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-1® (500 mg/m2 for 7 days)
Trial: 22416063
Drug: CBT-1® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-1® (500 mg/m2 for 7 days) + paclitaxel (135 mg/m2 on day 6)
Trial: 22416063
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg/m2 on day 6)
Trial: 22419719
Drug: Cancer-cachexia (CC)
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer-cachexia (CC)
Trial: 22420838
Drug: Aggressive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fever treatment strategy (acetaminophen 650 mg enterally every 6 hours for temperatures ≥ 38.3 °C; external cooling for temperatures ≥ 39.5 °C)
Trial: 22420838
Drug: Permissive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permissive fever treatment strategy (acetaminophen 650 mg every 6 hours for temperatures ≥ 40.0 °C; external cooling for temperatures ≥ 40.5 °C)
Trial: 22420838
Drug: Aggressive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fever treatment strategy
Trial: 22420838
Drug: Permissive fever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permissive fever treatment strategy
Trial: 22421227
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (stents and pharmacotherapy)
Trial: 22421340
Drug: Tocilizumab (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (4-8 mg/kg every 4 weeks)
Trial: 22422792
Drug: Pharmaceutical thrombosis
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH)
Trial: 22422826
Drug: Ruxolitinib 25
RxNorm normalized name: ruxolitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle), with dose escalation to 50 mg twice daily permitted for patients showing benefit.
Trial: 22423615
Drug: Intensity-modulated and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated and image-guided radiotherapy (IMRT-IGRT) by helical tomotherapy, delivering a dose of 50 Gy in fractions of 5 Gy.
Trial: 22424004
Drug: Collaborative quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative quality initiatives including radiation dose reduction and appropriate CCTA use
Trial: 22424178
Drug: Salbutamol (short-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (short-acting bronchodilator)
Trial: 22425095
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg with continuous daily dosing
Trial: 22426369
Drug: AS03-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H1N1 influenza vaccine (3.75µg HA)
Trial: 22429873
Drug: Inpatient weight-loss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient weight-loss program for children and adolescents (4 to 6 weeks duration) focusing on diet, physical activity, and behavior therapy.
Trial: 22431570
Drug: Obinutuzumab (GA101)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (GA101) administered in a dose-escalating fashion (3 per cohort, range 50/100-1200/2000 mg) for 8 × 21-day cycles
Trial: 22432117
Drug: Dopamine type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine type 2 receptor (D2R) availability measured using positron emission tomography and [(18)F]fallypride
Trial: 22432687
Drug: Cognitex supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitex supplementation (3 capsules per day for 12 weeks)
Trial: 22433615
Drug: Behavioral obesity
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral obesity treatment
Trial: 22436661
Drug: H-1PV by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1PV by intratumoral injection and administration into the walls of the tumor cavity during tumor resection
Trial: 22437560
Drug: Milk intake
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk intake (L/d)
Trial: 22438225
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention program (exercise, behavior, and nutrition therapy) for 1 year
Trial: 22438229
Drug: Alipogene tiparvovec
RxNorm normalized name: alipogene tiparvovec
DrugBank: Alipogene tiparvovec (DB13521)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Alipogene tiparvovec (AAV1-LPL(S447X)), administered at a dose of 1 × 10(12) genome copies per kilogram, intramuscularly.
Trial: 22438256
Drug: Obinutuzumab induction
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab induction (200-2000 mg IV weekly for 4 weeks) followed by maintenance every 3 months for a maximum of 8 doses
Trial: 28011903
Drug: Obinutuzumab maintenance
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab maintenance therapy
Trial: 22438987
Drug: Sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual (SL) administration of quadravalent HPV vaccine (n = 12)
Trial: 22438987
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of quadravalent HPV vaccine (n = 6)
Trial: 22439666
Drug: Cetuximab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (single agent treatment)
Trial: 22439666
Drug: Folfiri-cetuximab regimen
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Folfiri-cetuximab regimen (after initial treatment with cetuximab)
Trial: 23118984
Drug: MVA-NP+M1 vaccine
RxNorm normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-NP+M1 vaccine
Trial: 22443231
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL ropivacaine 0.75%
Trial: 22443231
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL ropivacaine 0.75%
Trial: 22443231
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL ropivacaine 0.75%
Trial: 22443293
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release (50-250 mg bid) during a 5-week titration and 7-week maintenance period.
Trial: 22443293
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release treatment for patients with neuropathic pain component.
Trial: 22443802
Drug: Neoadjuvant short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant short course intensity-modulated radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy)
Trial: 22445005
Drug: Concurrent temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent temozolomide with protocol radiotherapeutic treatment.
Trial: 22446154
Drug: Four-month daily
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-month daily pelvic floor muscle (PFM) strengthening exercise program at home
Trial: 22447809
Drug: Sildenafil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (40 or 80 mg)
Trial: 22448814
Drug: BCX1777 (forodesine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX1777 (forodesine) 100 mg/day
Trial: 22448814
Drug: BCX1777 (forodesine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX1777 (forodesine) 200 mg/day
Trial: 22448814
Drug: BCX1777 (forodesine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX1777 (forodesine) 300 mg/day
Trial: 22448921
Drug: Combotox (low-dose)
RxNorm normalized name: ibuprofen / oxycodone hydrochloride Oral Tablet [Combunox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combotox (low-dose) + Cytarabine (Ara-C)
Trial: 22448921
Drug: Combotox (high-dose)
RxNorm normalized name: ibuprofen / oxycodone hydrochloride Oral Tablet [Combunox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combotox (high-dose) + Cytarabine (Ara-C)
Trial: 22448921
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of Ara-C and Combotox
Trial: 22448921
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of Ara-C and Combotox
Trial: 22450529
Drug: Ultrasound-guided TAP
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg)
Trial: 22451423
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bendamustine (75 mg/m² on days 1 and 2), lenalidomide (10 mg on days 1-21), and dexamethasone (40 mg weekly) in a 28-day cycle
Trial: 22451423
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bendamustine, lenalidomide, and dexamethasone
Trial: 22452895
Drug: Afatinib 50
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 50 mg daily
Trial: 22452895
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg daily
Trial: 22454801
Drug: Aripiprazole (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15-30 mg/d)
Trial: 22454801
Drug: Lithium (900-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (900-1500 mg/d)
Trial: 22455454
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 150 mg eq (234 mg) administered via deltoid injection, with subsequent once-monthly injections of the same dose.
Trial: 22456429
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg intravenous, four doses every 3 weeks, then every 12 weeks for clinically stable patients)
Trial: 22456429
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg intravenous)
Trial: 22456661
Drug: Multiple-criteria model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-criteria model (≥ 2 of 3 abnormal ferritin < 12 μg/L, soluble transferrin receptor (TfR) > 8.3 mg/L, zinc protoporphyrin (ZP) > 80 μmol/mol)
Trial: 22456662
Drug: Zinc depletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc depletion (10 d, 0.3 mg Zn/d)
Trial: 22456662
Drug: Zinc repletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc repletion (7 d, 29.5 mg Zn/d)
Trial: 22456662
Drug: Zinc acclimation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc acclimation (7 d, 10.4 mg Zn/d)
Trial: 22461458
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies based on identified mutations and alterations in protein expression
Trial: 22465364
Drug: Subconjunctival sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival sirolimus (30 μL, 1320 μg)
Trial: 22466348
Drug: Mifepristone (300-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (300-1200 mg daily)
Trial: 22467666
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg on day 1) plus Trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/kg on day 1 of each subsequent cycle) plus Capecitabine (1,000 mg/m2 twice daily, days 1-14) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
Trial: 22467666
Drug: Bevacizumab, Trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab, Trastuzumab, and Capecitabine combination therapy.
Trial: 22469621
Drug: Ganglionic blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglionic blocker trimethaphan
Trial: 22469860
Drug: 2010-11 TIV
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2010-11 TIV (1 or 2 doses)
Trial: 22471422
Drug: Acupuncture treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatments
Trial: 22475206
Drug: lanreotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanreotide treatment for 6 months
Trial: 22476856
Drug: Lapatinib 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1500 mg/day
Trial: 22480772
Drug: Adalimumab induction
RxNorm normalized name: adalimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab induction therapy (160 mg/80 mg at Weeks 0/2), followed by 40 mg every other week for up to 20 weeks (40 mg weekly for flares/non-response after Week 12)
Trial: 22483738
Drug: Hypofractionated intensity-modulated
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent temozolomide (TMZ)
Trial: 22484295
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (PCV) 7, PCV10, PCV13
Trial: 22490570
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with taxane therapy (docetaxel or paclitaxel)
Trial: 22490570
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with taxane therapy
Trial: 22491916
Drug: Intravitreal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ketorolac (4 mg)
Trial: 22493299
Drug: Pomalidomide in
RxNorm normalized name: Product containing pomalidomide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide in combination with weekly dexamethasone (Pom/dex)
Trial: 22494428
Drug: Collaborative-care management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative-care management program (pharmacotherapy and combination trials)
Trial: 22494428
Drug: Collaborative-care management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative-care management program (psychotherapy and combination trials)
Trial: 22496496
Drug: Furosemide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (25 mg iv infusion)
Trial: 22497915
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral care without antiseptic)
Trial: 22499837
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with lower and higher doses of pyrimethamine with sulfadizine
Trial: 22503395
Drug: Primary surgery
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary surgery treatment (PST)
Trial: 22504934
Drug: Radioimmunotherapy (RIT)
RxNorm normalized name: mumps virus vaccine live, RIT-4385 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab tiuxetan at two dose levels (22 and 30 MBq/kg) combined with reduced intensity conditioning (RIC) using fludarabine, melphalan, and alemtuzumab followed by allogeneic hematopoietic cell transplantation (HCT).
Trial: 22506623
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 or 10 mg once daily
Trial: 22508772
Drug: apremilast (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast (both doses)
Trial: 22511492
Drug: lenalidomide/dexamethasone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide/dexamethasone treatment after nine cycles
Trial: 22511492
Drug: baseline (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baseline (before treatment)
Trial: 22511498
Drug: Rituximab, fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, fludarabine and mitoxantrone followed by 2-monthly rituximab maintenance
Trial: 22511498
Drug: Rituximab pharmacokinetics
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab pharmacokinetics
Trial: 22512844
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy using high-intensity focused ultrasound delivered to all known cancer lesions with a margin of normal tissue.
Trial: 22515800
Drug: 15% dextrose
RxNorm normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections at 1, 5, and 9 weeks, with as-needed treatments at weeks 13 and 17.
Trial: 22515800
Drug: 15% dextrose
RxNorm normalized name: Clinimix Sulfite Free, Amino Acids 5% with 15% Dextrose (Clinimix Sulfite-Free) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections.
Trial: 22515800
Drug: Low-dose opioid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose opioid analgesia for procedure-related pain.
Trial: 22517904
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d (RdC)
Trial: 22520270
Drug: TNFerade biologic
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFerade biologic (5 weekly injections, dose-escalated from 4 × 10(8) to 4 × 10(11) PU) combined with chemoradiotherapy (cisplatin 75 mg/m(2), 5-fluorouracil 1000 mg/m(2)/d for 96 hours, radiation therapy to 45 Gy)
Trial: 22520945
Drug: Oseltamivir (30-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (30-75 mg once daily for 6 weeks)
Trial: 22520945
Drug: Pooled safety
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled safety data from treatment studies (duration of 5 days) in children
Trial: 22522612
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion during exercise (N+)
Trial: 22522612
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during exercise (N-)
Trial: 22522612
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion without exercise (control)
Trial: 22524591
Drug: TExT-MED program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TExT-MED program (text message-based intervention, 3 messages daily for 3 weeks)
Trial: 22525392
Drug: Alkali-treated penicillin
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkali-treated penicillin G
Trial: 22525392
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G sodium (PGs)
Trial: 22525883
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks up to week 52
Trial: 22527084
Drug: Standardised drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised drug labelling used hospital-wide
Trial: 22527084
Drug: Standardised drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised drug labelling used in ICU
Trial: 22527084
Drug: Standardised drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised drug labelling by region
Trial: 22527084
Drug: Desire for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desire for ISO 26825 norm labelling from pharmaceutical industry